Instigation of the epoch of nanovaccines in cancer immunotherapy
© 2022 Wiley Periodicals LLC..
Cancer is an unprecedented proliferation of cells leading to abnormalities in differentiation and maturation. Treatment of primary and metastatic cancer is challenging. In addition to surgery, chemotherapy and radiation therapies have been conventionally used; however, they suffer from severe toxicity and non-specificity. Immunotherapy, the science of programming the body's own defense system against cancer has gained tremendous attention in the last few decades. However, partial immunogenic stimulation, premature degradation and inability to activate dendritic and helper T cells has resulted in limited clinical success. The era of nanomedicine has brought about several breakthroughs in various pharmaceutical and biomedical fields. Hereby, we review and discuss the interplay of tumor microenvironment (TME) and the immunological cascade and how they can be employed to develop nanoparticle-based cancer vaccines and immunotherapies. Nanoparticles composed of lipids, polymers and inorganic materials contain useful properties suitable for vaccine development. Proteinaceous vaccines derived from mammalian viruses, bacteriophages and plant viruses also have unique advantages due to their immunomodulation capabilities. This review accounts for all such considerations. Additionally, we explore how attributes of nanotechnology can be utilized to develop successful nanomedicine-based vaccines for cancer therapy. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology - 15(2023), 3 vom: 21. Mai, Seite e1870 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shah, Saurabh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
Date Completed 15.05.2023 Date Revised 24.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/wnan.1870 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349239282 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349239282 | ||
| 003 | DE-627 | ||
| 005 | 20231226042140.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/wnan.1870 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349239282 | ||
| 035 | |a (NLM)36410742 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shah, Saurabh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Instigation of the epoch of nanovaccines in cancer immunotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.05.2023 | ||
| 500 | |a Date Revised 24.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a Cancer is an unprecedented proliferation of cells leading to abnormalities in differentiation and maturation. Treatment of primary and metastatic cancer is challenging. In addition to surgery, chemotherapy and radiation therapies have been conventionally used; however, they suffer from severe toxicity and non-specificity. Immunotherapy, the science of programming the body's own defense system against cancer has gained tremendous attention in the last few decades. However, partial immunogenic stimulation, premature degradation and inability to activate dendritic and helper T cells has resulted in limited clinical success. The era of nanomedicine has brought about several breakthroughs in various pharmaceutical and biomedical fields. Hereby, we review and discuss the interplay of tumor microenvironment (TME) and the immunological cascade and how they can be employed to develop nanoparticle-based cancer vaccines and immunotherapies. Nanoparticles composed of lipids, polymers and inorganic materials contain useful properties suitable for vaccine development. Proteinaceous vaccines derived from mammalian viruses, bacteriophages and plant viruses also have unique advantages due to their immunomodulation capabilities. This review accounts for all such considerations. Additionally, we explore how attributes of nanotechnology can be utilized to develop successful nanomedicine-based vaccines for cancer therapy. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a dendritic cells | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a nanovaccine | |
| 650 | 7 | |a Cancer Vaccines |2 NLM | |
| 700 | 1 | |a Famta, Paras |e verfasserin |4 aut | |
| 700 | 1 | |a Tiwari, Vinod |e verfasserin |4 aut | |
| 700 | 1 | |a Kotha, Arun K |e verfasserin |4 aut | |
| 700 | 1 | |a Kashikar, Rama |e verfasserin |4 aut | |
| 700 | 1 | |a Chougule, Mahavir Bhupal |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Young Hun |e verfasserin |4 aut | |
| 700 | 1 | |a Steinmetz, Nicole F |e verfasserin |4 aut | |
| 700 | 1 | |a Uddin, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Shashi Bala |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastava, Saurabh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology |d 2009 |g 15(2023), 3 vom: 21. Mai, Seite e1870 |w (DE-627)NLM192898752 |x 1939-0041 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:3 |g day:21 |g month:05 |g pages:e1870 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/wnan.1870 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 3 |b 21 |c 05 |h e1870 | ||